63 related articles for article (PubMed ID: 22544017)
41. A long-term, phase 2, multicenter, randomized, open-label, comparative safety study of pomaglumetad methionil (LY2140023 monohydrate) versus atypical antipsychotic standard of care in patients with schizophrenia.
Adams DH; Kinon BJ; Baygani S; Millen BA; Velona I; Kollack-Walker S; Walling DP
BMC Psychiatry; 2013 May; 13():143. PubMed ID: 23694720
[TBL] [Abstract][Full Text] [Related]
42. The G Protein-Coupled Glutamate Receptors as Novel Molecular Targets in Schizophrenia Treatment-A Narrative Review.
Kryszkowski W; Boczek T
J Clin Med; 2021 Apr; 10(7):. PubMed ID: 33918323
[TBL] [Abstract][Full Text] [Related]
43. Evaluation of single and multiple doses of a novel mGlu2 agonist, a potential antipsychotic therapy, in healthy subjects.
McColm J; Brittain C; Suriyapperuma S; Swanson S; Tauscher-Wisniewski S; Foster J; Soon D; Jackson K
Br J Clin Pharmacol; 2017 Aug; 83(8):1654-1667. PubMed ID: 28156011
[TBL] [Abstract][Full Text] [Related]
44. Perspectives on the mGluR2/3 agonists as a therapeutic target for schizophrenia: Still promising or a dead end?
Li ML; Hu XQ; Li F; Gao WJ
Prog Neuropsychopharmacol Biol Psychiatry; 2015 Jul; 60():66-76. PubMed ID: 25724760
[TBL] [Abstract][Full Text] [Related]
45. A multicenter, inpatient, phase 2, double-blind, placebo-controlled dose-ranging study of LY2140023 monohydrate in patients with DSM-IV schizophrenia.
Kinon BJ; Zhang L; Millen BA; Osuntokun OO; Williams JE; Kollack-Walker S; Jackson K; Kryzhanovskaya L; Jarkova N;
J Clin Psychopharmacol; 2011 Jun; 31(3):349-55. PubMed ID: 21508856
[TBL] [Abstract][Full Text] [Related]
46. Comment on: "Adverse events in healthy subjects exposed to single and multiple doses of LY2140023 monohydrate" by Ayan-Oshodi et al (J Clin Psychopharmacol 2012;32[3]:408-411).
Seeman P
J Clin Psychopharmacol; 2013 Apr; 33(2):280. PubMed ID: 23422392
[No Abstract] [Full Text] [Related]
47. A Double-Blind, Placebo-Controlled Comparator Study of LY2140023 monohydrate in patients with schizophrenia.
Downing AM; Kinon BJ; Millen BA; Zhang L; Liu L; Morozova MA; Brenner R; Rayle TJ; Nisenbaum L; Zhao F; Gomez JC
BMC Psychiatry; 2014 Dec; 14():351. PubMed ID: 25539791
[TBL] [Abstract][Full Text] [Related]
48. Effects of a novel mGlu₂/₃ receptor agonist prodrug, LY2140023 monohydrate, on central monoamine turnover as determined in human and rat cerebrospinal fluid.
Lowe S; Dean R; Ackermann B; Jackson K; Natanegara F; Anderson S; Eckstein J; Yuen E; Ayan-Oshodi M; Ho M; McKinzie D; Perry K; Svensson K
Psychopharmacology (Berl); 2012 Feb; 219(4):959-70. PubMed ID: 21847569
[TBL] [Abstract][Full Text] [Related]
49. Relative contributions of presystemic and systemic peptidases to oral exposure of a novel metabotropic glutamate 2/3 receptor agonist (LY404039) after oral administration of prodrug pomaglumetad methionil (LY2140023).
Annes WF; Long A; Witcher JW; Ayan-Oshodi MA; Knadler MP; Zhang W; Mitchell MI; Cornelissen K; Hall SD
J Pharm Sci; 2015 Jan; 104(1):207-14. PubMed ID: 25382826
[TBL] [Abstract][Full Text] [Related]
50. Adverse events in healthy subjects exposed to single and multiple doses of LY2140023 monohydrate: pooled results from 10 phase 1 studies.
Ayan-Oshodi M; Wondmagegnehu ET; Lowe SL; Kryzhanovskaya L; Walker DJ; Kinon BJ
J Clin Psychopharmacol; 2012 Jun; 32(3):408-11. PubMed ID: 22544017
[TBL] [Abstract][Full Text] [Related]
51. Group II metabotropic glutamate receptor agonists and positive allosteric modulators as novel treatments for schizophrenia.
Fell MJ; McKinzie DL; Monn JA; Svensson KA
Neuropharmacology; 2012 Mar; 62(3):1473-83. PubMed ID: 21704048
[TBL] [Abstract][Full Text] [Related]
52. Inhaled loxapine for agitation revisited: focus on effect sizes from 2 Phase III randomised controlled trials in persons with schizophrenia or bipolar disorder.
Citrome L
Int J Clin Pract; 2012 Mar; 66(3):318-25. PubMed ID: 22226343
[TBL] [Abstract][Full Text] [Related]
53. [Targeting metabotropic glutamate receptors to develop novel antipsychotics].
Chaki S; Yoshida S; Okuyama S
Nihon Shinkei Seishin Yakurigaku Zasshi; 2010 Nov; 30(5-6):207-13. PubMed ID: 21226317
[TBL] [Abstract][Full Text] [Related]
54.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
55.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
56.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
57.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
58.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
59.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
60.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]